中华泌尿外科杂志
中華泌尿外科雜誌
중화비뇨외과잡지
CHINESE JOURNAL OF UROLOGY
2014年
8期
571-574
,共4页
邱忠凯%孔垂泽%张哲%陈志鹏
邱忠凱%孔垂澤%張哲%陳誌鵬
구충개%공수택%장철%진지붕
肾透明细胞癌%Netrin-1%免疫组化
腎透明細胞癌%Netrin-1%免疫組化
신투명세포암%Netrin-1%면역조화
Clear cell renal carcinoma%Netrin-1%Immunohistochemistry
目的 探讨神经轴突导向分子Netrin-1在肾透明细胞癌组织中的表达及其与临床病理和预后的关系.方法 选取原发性肾透明细胞癌组织及其癌旁组织48例.男26例,女22例.年龄26～83岁,平均60岁,中位年龄62岁.48例均为首次发病,均经常规病理诊断确诊,术前未经过放化疗及生物治疗.Fuhrman分级Ⅰ级6例,Ⅱ级6例,Ⅲ级27例,Ⅳ级9例.2010年AJCC肾癌分期Ⅰ ～Ⅱ期20例,Ⅲ～Ⅳ期28例.采用免疫组化技术检测标本中Netrin-1蛋白的表达,结合临床病理资料进行分析所有病例随访5年以上,生存分析采用Kaplan-Meier法,组间差异采用Log-rank检验.结果 48例肾透明细胞癌组织中Netrin-1蛋白高表达率为71％ (34/48),癌旁正常肾组织为17％(8/48),组间比较差异有统计学意义(P＜0.05).肾透明细胞癌组织中Fuhrman Ⅰ～Ⅱ级与Ⅲ～Ⅳ级的Netrin-1蛋白高表达率分别为42％(5/12)、81％ (29/36),AJCC临床分期Ⅰ～Ⅱ期与Ⅲ～Ⅳ期者分别为55％(11/20)、82％(23/28),组间比较差异均有统计学意义(P＜0.05).Netrin-1蛋白高表达组与低表达组患者术后5年生存率分别为62％(21/34)、79％(11/14),存在生存曲线趋势差异,但组间差异无统计学意义(P＞0.05).结论 Netrin-1蛋白在肾透明细胞癌发生和发展过程中起重要作用,可作为肾透明细胞癌的新型特异性肿瘤标志物,并有望成为肾透明细胞癌治疗的靶标.
目的 探討神經軸突導嚮分子Netrin-1在腎透明細胞癌組織中的錶達及其與臨床病理和預後的關繫.方法 選取原髮性腎透明細胞癌組織及其癌徬組織48例.男26例,女22例.年齡26～83歲,平均60歲,中位年齡62歲.48例均為首次髮病,均經常規病理診斷確診,術前未經過放化療及生物治療.Fuhrman分級Ⅰ級6例,Ⅱ級6例,Ⅲ級27例,Ⅳ級9例.2010年AJCC腎癌分期Ⅰ ～Ⅱ期20例,Ⅲ～Ⅳ期28例.採用免疫組化技術檢測標本中Netrin-1蛋白的錶達,結閤臨床病理資料進行分析所有病例隨訪5年以上,生存分析採用Kaplan-Meier法,組間差異採用Log-rank檢驗.結果 48例腎透明細胞癌組織中Netrin-1蛋白高錶達率為71％ (34/48),癌徬正常腎組織為17％(8/48),組間比較差異有統計學意義(P＜0.05).腎透明細胞癌組織中Fuhrman Ⅰ～Ⅱ級與Ⅲ～Ⅳ級的Netrin-1蛋白高錶達率分彆為42％(5/12)、81％ (29/36),AJCC臨床分期Ⅰ～Ⅱ期與Ⅲ～Ⅳ期者分彆為55％(11/20)、82％(23/28),組間比較差異均有統計學意義(P＜0.05).Netrin-1蛋白高錶達組與低錶達組患者術後5年生存率分彆為62％(21/34)、79％(11/14),存在生存麯線趨勢差異,但組間差異無統計學意義(P＞0.05).結論 Netrin-1蛋白在腎透明細胞癌髮生和髮展過程中起重要作用,可作為腎透明細胞癌的新型特異性腫瘤標誌物,併有望成為腎透明細胞癌治療的靶標.
목적 탐토신경축돌도향분자Netrin-1재신투명세포암조직중적표체급기여림상병리화예후적관계.방법 선취원발성신투명세포암조직급기암방조직48례.남26례,녀22례.년령26～83세,평균60세,중위년령62세.48례균위수차발병,균경상규병리진단학진,술전미경과방화료급생물치료.Fuhrman분급Ⅰ급6례,Ⅱ급6례,Ⅲ급27례,Ⅳ급9례.2010년AJCC신암분기Ⅰ ～Ⅱ기20례,Ⅲ～Ⅳ기28례.채용면역조화기술검측표본중Netrin-1단백적표체,결합림상병리자료진행분석소유병례수방5년이상,생존분석채용Kaplan-Meier법,조간차이채용Log-rank검험.결과 48례신투명세포암조직중Netrin-1단백고표체솔위71％ (34/48),암방정상신조직위17％(8/48),조간비교차이유통계학의의(P＜0.05).신투명세포암조직중Fuhrman Ⅰ～Ⅱ급여Ⅲ～Ⅳ급적Netrin-1단백고표체솔분별위42％(5/12)、81％ (29/36),AJCC림상분기Ⅰ～Ⅱ기여Ⅲ～Ⅳ기자분별위55％(11/20)、82％(23/28),조간비교차이균유통계학의의(P＜0.05).Netrin-1단백고표체조여저표체조환자술후5년생존솔분별위62％(21/34)、79％(11/14),존재생존곡선추세차이,단조간차이무통계학의의(P＞0.05).결론 Netrin-1단백재신투명세포암발생화발전과정중기중요작용,가작위신투명세포암적신형특이성종류표지물,병유망성위신투명세포암치료적파표.
Objective To investigate the expression of Netrin-1 protein in human renal clear cell carcinoma (RCCC) and the relationships between Netrin-1,pathology and prognosis.Methods Fortyeight cases of RCCC and their adjacent tissues were selected for study,including 26 males and 22 females.The median age was 62 years (range,26 to 83 years).All 48 patients were onset for the first time,confirmed by pathology.All cases had no radiotherapy,chemotherapy or biological treatment before operation.Fuhrman grade:6 cases in grade Ⅰ,6 cases,in grade Ⅱ,27 cases in grade Ⅲ and 9 cases in grade Ⅳ.The AJCC staging in 2010:20 cases in stage Ⅰ-Ⅱ],28 cases in stage Ⅲ-Ⅳ.The expression of Netrin-1 protein was detected by immunohistochemical staining and its clinical significance was analyzed.All cases were followed up for more than 5 years.Survival analysis lines were made by Kaplan-Meier method and the difference between groups was tested by the Log-rank test.Results The expression of Netrin-1 protein was higher in renal cancers [71％ (34/48)] than that in the adjacent normal tissues [17％ (8/48)] (P＜0.05).Netrin-1 protein expression rates were 42％(5/12) in Fuhrman Ⅰ-Ⅱ tumors and 81％ (29/36) in Fuhrman Ⅲ-Ⅳ tumors,while 55％ (11/20) in stage Ⅰ-Ⅱ and 82％ (23/28) in stage Ⅲ-Ⅳ,respectively (P＜0.05).The 5-year survival rate in high protein expression group and in low protein expression group was 62％ (21/ 34) and 79％ (11/14).The survival curve had different trend,with no significant difference between groups (P＞0.05).Conclusions Netrin-1 protein plays an important role in the development of RCCC.It might be a new specific tumor marker of RCCC,and might become a new target in treatment of RCCC.
